ImmunoGen,Inc. (NASDAQ:IMGN) Files An 8-K Other Events

ImmunoGen,Inc. (NASDAQ:IMGN) Files An 8-K Other Events
Item 8.01 Other Events.

On May16, 2018,ImmunoGen,Inc. (“ImmunoGen”) issued a press release announcing positive findings from the FORWARD II trial of mirvetuximab soravtansine combination regimens with Avastin®(bevacizumab) and carboplatin. ImmunoGen also announced that on May17, 2018 at 8:00 a.m.ET, it will host an investor conference call to discuss new data from the FORWARD II trial. A copy of such press release is being filed as Exhibit99.1 to this report and is incorporated herein by reference. A copy of the investor presentation to be used on the investor conference call is being furnished as Exhibit99.2 to this report.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

The information set forth in Exhibit99.2 shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.


IMMUNOGEN INC Exhibit
EX-99.1 2 a18-13726_1ex99d1.htm EX-99.1 Exhibit 99.1     ImmunoGen Announces Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination Regimens with Avastin® and Carboplatin in Ovarian Cancer   Data from Avastin Cohort to be Presented at 2018 ASCO Annual Meeting   Updated Data from Carboplatin Dose-Escalation Cohort Demonstrate Increased Response Rate and Durable Benefit with Longer-Term Follow Up   Conference Call Scheduled for 8 a.m. ET on Thursday,…
To view the full exhibit click here

About ImmunoGen,Inc. (NASDAQ:IMGN)

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.

An ad to help with our costs